Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig + Chemotherapy in Previously Untreated TNBC
NCT07173751Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Oct 2025
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Arm 1: Pumitamig + TPC Chemotherapy with Arm 2: Placebo + TPC Chemotherapy (2 arms). Primary endpoints: Progression-Free Survival at 32 months and Overall Survival at 49 months. Started Oct 2025; status: recruiting.
02
Drugs
pumitamig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07173751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173751.